Nine of ten patients who had previously received CD19-directed immunotherapy achieved CR, including all five patients who had enrolled with CD19dim- or CD19-negative B-ALL and one patient who was refractory to both CD19 CAR T cell and blinatumomab therapies. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.